SCN9A
Sodium channel protein type 9 subunit alpha
As of the edition of 20 October 2026, SCN9A (sodium channel protein type 9 subunit alpha, UniProt Q15858) has 61 drugs tested at it and 18 companies on the list, 4 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15858
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 44
- Disease areas
- Nervous system; Mental health; Injuries; Cancer; Bones, joints and muscles; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
- Registered trials of its drugs
- 2,714
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 44 |
| Active | 5 |
| Went quiet | 8 |
| Stopped | 3 |
| Withdrawn from market | 1 |
| Total | 61 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lidocaine | Marketed | Phase 4 | none listed |
| Ropivacaine | Marketed | Phase 4 | none listed |
| Topiramate | Marketed | Phase 4 | none listed |
| Lamotrigine | Marketed | Phase 4 | none listed |
| Carbamazepine | Marketed | Phase 4 | none listed |
| Lacosamide | Marketed | Phase 4 | Ended 2026 |
| Riluzole | Marketed | Phase 4 | none listed |
| Tetracaine | Marketed | Phase 4 | none listed |
| Eslicarbazepine acetate | Marketed | Phase 4 | Ended 2026 |
| Zonisamide | Marketed | Phase 4 | none listed |
| Phenytoin | Marketed | Phase 4 | none listed |
| Articaine | Marketed | Phase 4 | none listed |
12 of 61 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 5 |
| Engaged | 8 |
| Undetermined | 1 |
| Total on the list | 18 |
The other 15 companies at SCN9A
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at SCN9A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.